Table 6.
Vaccine efficacy against P. falciparum disease (ATP Cohort for Efficacy)
|
RTS,S/AS02D |
Hepatitis B Vaccine |
Point estimate of VE adjusted for covariates |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects (N) | No. of events | PYAR | Subjects (N) | No. of events | PYAR | (%) | 95% CI | P value | |
|
Primary Case Definition: multiple episodes | |||||||||
|
Months 2.5 – 14 | |||||||||
| 146 |
18 |
124.48 |
151 |
30 |
127.91 |
50.7 |
−6.5 |
77.1 |
0.072 |
|
Months 2.5 – 20 | |||||||||
| 146 |
42 |
193.41 |
151 |
51 |
198.29 |
26.7 |
−33.1 |
59.6 |
0.307 |
|
Primary Case Definition: first or only | |||||||||
|
Months 2.5 – 14 | |||||||||
| 146 |
13 |
121.04 |
151 |
24 |
121.34 |
53.6 |
8.6 |
76.4 |
0.026 |
|
Months 2.5 – 20 | |||||||||
| 146 | 26 | 181.92 | 151 | 34 | 178.56 | 34.9 | −8.8 | 61.1 | 0.101 |
PYAR: Episodes/Person Years at Risk; VE: Vaccine Efficacy (1-HR); CI: Confidence Interval; p value from Cox PH model; Poisson regression for multiple episodes.